Category:
Peptides
CAS NO:
1607799-13-2
Standard:
In-house Standards,
Bremelanotide was developed by Palatin Technologies, it was first described in the literature in 2003 when it was known by the investigational code PT-141. Bremelanotide was granted FDA approval on 21 June 2019.